Blog

The latest thoughts from Medicines Law & Policy partners.

Why The Request By Least Developed Countries For An Extension Of The Transitional Period...

On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...

The European Commission’s proposal for an EU wide compulsory licensing mechanism

In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless

Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...

Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
INB co-chairs, Precious Matsoso from South Africa and Roland Driece from the Netherlands opening the session on 18 June

Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...

Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...

Price, profit and the Covid-19 health technology pool: The example of remdesivir

We cannot yet know the precise trajectory of the Covid-19 pandemic, nor which therapies or vaccines will eventually prove most effective in its treatment...

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...

According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...

Brazil’s Federal Court Reviews Medicines Mailbox Patents

This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...